Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of inhaled treprostinil in fibrotic lung disease
NL-OMON56110Recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of treprostinil in idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis (PF) and interstitial lung disease (ILD), sponsored by United Therapeutics Corporation. Started Jul 2024; status: recruiting.
02
Drugs
treprostinil
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NL-OMON56110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56110.